Treace Medical Concepts, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John T. Treace
- Full Time Employees
- 450
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Palmetto Park Place Ponte Vedra FL United States of America 32081
- IPO Date
- Apr 23, 2021
- CIK
- 0001630627
- Website
- treace.com
- Similar Companies
- Business
- Treace Medical Concepts, Inc. (Nasdaq: TMCI) develops and markets minimally invasive foot and ankle medical devices designed for surgical correction of bunion deformities and related midfoot and forefoot pathologies. The company offers a comprehensive portfolio of proprietary orthopedic products, including the Lapiplasty 3D Bunion Correction System, the CrossRoads Fixation System, the SpeedPlate Fixation Systems, the Adductoplasty Lapidus Plate, the Hammertoe Fixation Systems, and the Mini-Bunion Kit; these systems utilize patented nitinol compression technology and titanium implants to enable reproducible, stable corrections with reduced complication risks. Treace serves orthopedic foot and ankle surgeons and podiatric surgeons primarily in the United States, with operations focused on the domestic market from its headquarters in Ponte Vedra Beach, Florida, where the company was founded in 2014. In recent developments, Treace expanded its product offerings with the launch of the Mini-Bunion System in 2024 and the Adductoplasty Lapidus Plate in early 2025, enhancing minimally invasive options for juvenile and adult bunion corrections; the company also strengthened its commercial infrastructure through surgeon education programs and reported robust procedure growth amid ongoing reimbursement advancements.
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
Treace Medical Concepts Q2 Earnings Call Highlights
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI)
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
Treace to Present at the Sidoti Small Cap Conference
Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Treace Medical Concepts Q1 Earnings Call Highlights
Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
Treace Medical Concepts Reports First Quarter 2026 Financial Results
Treace to Report First Quarter 2026 Financial Results on May 8, 2026
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
Treace Medical Concepts (NASDAQ:TMCI) and PAVmed (NASDAQ:PAVM) Head-To-Head Survey
Treace Medical Concepts Q4 Earnings Call Highlights
Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results